English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
ESG Reports
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
Announcements & Circulars
The announcement begins in December 2019
FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, JUNE 12, 2024
2024-05-20
NOTICE OF ANNUAL GENERAL MEETING
2024-05-20
(1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES (INCLUDING RESELL OR TRANSFER TREASURY SHARES); (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; (4) PROPOSED AMENDMENTS TO THE POST-IPO SHARE OPTION SCHEME; (5) PROPOSED AMENDMENTS TO THE RESTRICTED SHARE AWARD SCHEME; (6) PROPOSED REFRESHMENT OF THE SCHEME MANDATE LIMIT; AND (7) NOTICE OF ANNUAL GENERAL MEETING
2024-05-20
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
2024-05-07
2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
2024-04-29
(1) GRANT OF SHARE OPTIONS UNDER THE POST-IPO SHARE OPTION SCHEME; AND (2) GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD SCHEME
2024-04-23
VOLUNTARY ANNOUNCEMENT – UPDATES ON RESULTS OF A PHASE I CLINICAL TRIAL OF JSKN003 FOR THE TREATMENT OF HER2-EXPRESSING ADVANCED SOLID TUMORS FOR PRESENTATION AT 2024 AACR ANNUAL MEETING
2024-04-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
2024-04-03
(1) REVISION OF ANNUAL CAP FOR EXISTING CONTINUING CONNECTED TRANSACTION; AND (2) RENEWAL OF THE MASTER TECHNICAL SERVICE AGREEMENT
2024-04-02
CONNECTED TRANSACTION ANNOUNCEMENT - RENEWAL OF THE LEASE AGREEMENT
2024-03-28
3
4
5
6
7
8
9
PREV
6/27
NEXT